Clinical Trial Update: Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risankizumab to secukinumab in moderate-to-severe plaque psoriasis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)
• Secukinumab (secukinumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-07-13